Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Marketplace Directory

QuidelOrtho adds fentanyl test to Vitros systems

June 2024—QuidelOrtho has added the Ark Fentanyl II assay to its U.S. Vitros XT 7600 and 5600 integrated systems and Vitros 4600 chemistry system. It is offered as a MicroTip Partnership Assay; MPAs are validated for use on MicroTip-capable Vitros systems through a collaboration between contracted vendors and a team of QuidelOrtho scientists and professionals. The assay provides a result in less than 10 minutes.

CLSI publishes three new AST documents

June 2024—The Clinical and Laboratory Standards Institute has released a new update of “M100: Performance Standards for Antimicrobial Susceptibility Testing” (34th edition) and revised editions of “M02: Performance Standards for Antimicrobial Disk Susceptibility Tests” (14th edition) and “M07: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically” (12th edition). The tables presented in M100 represent the most current information for drug selection, interpretation, and quality control using procedures defined in CLSI standards M02, M07, and M11 (“Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria”).

Sebia gets FDA clearance for Capillarys 3 DBS

June 2024—Sebia announced it has received FDA 510(k) clearance for its Capillarys 3 DBS instrument. The capillary electrophoresis-based automated analyzer is intended for the detection of normal hemoglobins (F and A) and abnormal hemoglobins (S, C, E, D, and Barts) in blood collected on filter paper from newborns. The instrument can analyze up to eight 96-well microplates and has a throughput of 70 tests per hour.

FDA clears Leica Biosystems Aperio GT 450 DX

June 2024—Leica Biosystems announced that its flagship digital pathology system, Aperio GT 450 DX, has received 510(k) clearance from the U.S. Food and Drug Administration. The Aperio GT 450 DX is proven technology that offers both SVS and Native DICOM and consistently delivers high-quality images at a turnaround time of less than 32 seconds per slide.

Next-gen StatStrip glucose system gets 510(k) clearance

June 2024—Nova Biomedical announced the U.S. launch of its 510(k)-cleared, next-generation StatStrip glucose hospital meter system. New features include a Linux operating system with enhanced cybersecurity, RFID data entry, wireless charging, and a hematocrit range of five to 75 percent. The meter is FDA cleared for testing patients who are critically ill.

FDA clears LifeScale AST system

June 2024—Affinity Biosensors announced that its Life­Scale AST system received FDA 510(k) clearance. The multiplex in vitro diagnostic test uses a microfluidic sensor and resonant frequency to calculate organism concentration and/or mass distribution for quantitative antimicrobial susceptibility testing. Testing is performed directly on blood cultures signaled as positive by a continuous monitoring blood culture system and confirmed by Gram stain. Results are available in less than five hours.

Verichem reference materials for ethanol, lithium testing

June 2024—Verichem Laboratories now offers a liquid-stable, ready-to-use set of multilevel clinical reference materials for the calibration verification of ethanol assays. The company also offers two multi­level test kits of clinical reference materials for the calibration verification of lithium assays intended for use with direct and indirect ion selective electrodes, colorimetric assays, and flame photometers.

Recordati Rare Diseases introduces educational website

May 2024—Recordati Rare Diseases has introduced its new educational website, Think iMCD, at https://thinkimcd.us. The platform is tailored for pathologists and offers comprehensive support for the diagnostic process of idiopathic multicentric Castleman disease (iMCD). The website provides an overview of iMCD diagnostic criteria, practical steps for assessing lymph node biopsies, and links to additional resources for understanding CD/iMCD. Designed to enhance professional awareness and comprehension, the site aims to be a valuable tool for the medical community.

Leica publishes guide to good histology practice

May 2024—Leica Biosystems has published “101 Steps to Better Histology—A Practical Guide to Good Histology Practice,” written by histology consultant Geoffrey Rolls. The guide provides practical advice on best-practice techniques and simple ways to avoid common errors and covers each aspect of the histology process: specimen collection, grossing, processing, embedding, and sectioning and staining. It is downloadable free of charge on Leica’s “Knowledge Pathway” site.